1Weiyi C H,Shinsuke L, Diane C, et al. Heterologous promoters fused to Bcl-6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during Bcell differentitation. Blood, 1998, 91:603 -607.
2Lavelle D, Chen Y H, Hankewych M, et al. Histone deacetylase inhibitors increase P21WAF and induce apoptosis of human myeloma cell lines independent of de creased IL-6 receptor expression. Am J Hema, 2001,68:170-178.
3Dhordain P,Lin R J,Quief S,et al. The LAZ3 (BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res, 1998,26: 4645 - 4651.
4Bereshchenko O R,Gu W,Dalla-Favera R,et al. Acetylation Inactivates the Transcriptional Repressor BCL-6.Nat Genet,2002,32: 606- 613.
5Murray A, Erle S, et al. Modulation of histone acetyl transferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol, 2000,20:5722-5735.
6Wang L, Grossman S R, Kieff E, et al. Epstein-Barr virus nuclear protein 2 interacts with P300. CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Nat1 AcadSciUSA, 2000,97:430-435.
7Bryant H, Farrell P J, et al. Signal transduction and transcription factor modification during reactivation of EB virus from latency. J Virol, 2002, 76:10920-10928.
8Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deaccetylase inhibitor, on hu man lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol, 2002, 64: 1079- 1090.
9Richard L, Robey R, Sandor V, et al. Inhibitors of histone deacetylation, Depsipeptide ( FR901228 ), in the treatment of peripheral and cutaneous T cell lymphoma:a case in report. Blood,2001,98:2865-2868.
10Cress W D, Seto E. Histone deacetylase, transcription control, and cancer. J Cell Physiol, 2000,184: 1 - 16.
2YANG X J. The diverse superfarnily of lysine acetyltransferases and their roles in leukem and other diseases. Maclerc Acids Research, 2004,32 ; 959-- 976.
3CHAN H M, LATHANGUE N B. p300/CBP proteins: HATS for transcriptional bridges and scaffolds [J]. Journal Cell Science, 2001,114 2363-- 2373.
4VIVIENNE I R, ANDRAW L K,ELIABETH A T, et al. Distinct Roles for CREB-binding protein and p300 in hematopieotic stem cell self-renewal [J]. PNAS, 2002,99L:14789-- 14794.
5LIVENGOOD JA, SCOGGIN KE, VAN OK, et al. P53 trancscriptional activity is mediated through the SRC 1 interacting Domain of CBP/p300[J]. The Journal Biological Chemistry, 2002, 277 : 9054 -- 9061.
6IYER N G, OZDAG H, CALDAS C. p300/CBP and cancer[J]. Oncogene, 2004,23:4225- 4231.
7WANG JX, HBSHINO T, REDNER R, et al. ETO fusion Partner in t[8. 21)acute myeloid leukemia repress transcription by interaction with human N-eoR/ Msin3/HDAC1 eomplexs [J]. Proe Natl Aead Sei USA, 1998,95 : 10860-10865.
8RICHARD H, SMOLIK S. CBP/p300 in cellgrowth, trasformation, and development [J]. Gene Development, 2002,14 : 1553 -- 1577.
9HAKE SB, XIAO A, ALLIS CD. Linking the epigenetic language Covalent histone modifications to cancer[J]. British Journal Cancer, 2004,90:761 -769.
10IMAMURA T, KAKAZU N, HIBI S, et al. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastie syndrome with a novel chromosomal transloeation t(2;8) (p23;p11)[J]. GenesChromosomes-Cancer, 2003, 36 : 413-- 419.
